Chronic Myeloid Leukemia (CML) Matt Walter Markey Program October 21, 2014
|
|
- Oscar Singleton
- 7 years ago
- Views:
Transcription
1 Chronic Myeloid Leukemia (CML) Matt Walter Markey Program October 21, 2014
2 CML: paradigm for cancer treatment Identify primary genetic abnormality Develop an agent that targets that abnormality Monitor for efficacy Overcoming resistance
3 Chronic Myeloid Leukemia Session Overview 1. Matt Walter = Hematopoiesis overview 2. Dan Link = Signaling, animal models 3. Peter Westervelt = Clinical overview * 4. Steve Oh = Imatinib preclinical/clinical 5. Geoff Uy = Imatinib resistance * 6. Rizwan Romee = Bone marrow transplant * 7. Jerry Radich = Guest speaker on CML 8. Last class = round table lunch * Patient interviews
4 Hematopoiesis Stem cell Bone marrow Progenitors Blood Terminally differentiated NEJM (2006) 354;19, p.2034
5 Hematopoietic growth factor (HGF) signaling Receptor Tyrosine Kinase (RTK) (ABL, non Receptor TK) *Frequent targets for mutation in leukemia * * * * * NEJM (2006) 354;19, p.2034
6 Classification of Leukemias Lymphoid Myeloid CLL Chronic Lymphocytic Leukemia ALL Acute Lymphocytic Leukemia CML Chronic Myeloid Leukemia AML Acute Myeloid Leukemia 10/100,000 1/100,000 2/100,000 (~6,000 new/year) Acute = fast clinical progression. Block in differentiation (weeks to months) 5/100,000
7 Chronic Leukemias & MPNs: differentiation occurs Blood Terminally differentiated Essential Thrombocytosis (ET) Chronic Myelo Monocytic Leukemia (CMML) Polycythemia Vera (PV) Chronic Myeloid Leukemia (CML) Chronic Lymphocytic Leukemia (CLL) Myeloproliferative Neoplasms (MPN)
8 Genetics of Myeloproliferative Neoplasms (MPN) Essential Thrombocytosis (ET) (JAK2) Myeloid Neoplasm with Eosinophilia (PDGFRA/B) Polycythemia Vera (PV) (JAK2) Chronic Myeloid Leukemia (CML) (BCR:ABL) Mastocytosis (KIT) Mutation/rearrangement of tyrosine kinase genes
9 Westervelt CML 1.4:1 ( : ), average age 45 Increased blood WBC (>25k/uL) Minimal/no fibrosis or dysplasia Granulocyte maturation basophil Normal peripheral blood CML blood eosinophil Normal BM Peter Maslak, ASH Image Bank 2011;
10 CML chronic Blastic phase (block in differentiation)
11 Westervelt CML Chronic phase Driven by BCR ABL 50% no symptoms, found on routine CBC WBC PB, BM, spleen Fatigue, weight loss, abdominal fullness, bleeding, sweats, large spleen/liver 75% had accelerated phase 3 18 months prior to blastic phase Blast phase Acquire secondary mutations 1/3 = ALL, 2/3 = AML Decreased response to treatment and duration not long lasting
12 BCR:ABL fusion in CML Cytogenetics = t(9;22), Philadelphia chromosome + (Ph+), (100% BCR ABL transcript) BCR ABL transcript +
13 Flemming draws first chromosome Waldeyer coins chromosome Painter reports 48 chromosomes = normal Tjio reports 46 chromosomes = normal syndromes Down +21 Turner XO Klinefelter XXY 1890 von Hansemann observes mitotic aberrations in tumor cells dark ages Technical problems 1. better cultures 2. hypotonic solution 3. colchicine 1960 Nowell & Hungerford = Ph chromosome & CML The findings suggest a causal relationship between the chromosomal abnormality observed and chronic granulocytic leukemia.
14 Chromosome Gene Drug Baltimore, v Abl Nowell & Hungerford = Ph chromosome & CML Rowley reports Ph chr. = t(9;22) Heisterkamp, Stephenson, Groffen, Grosveld clone genes at breakpoints (BCR, ABL) Druker uses Gleevec to treat CML
15 v ABL oncogene Lymphosarcoma: virus induced thymic independent disease in mice. Abelson HT, Rabstein LS. Cancer Res Aug;30(8): v Abl Cell Dec;18(4): Cell Dec;22(3):777 85
16 (coil coil) p190 = 20 30% ALL (most B cell) p210 (p230) = 99% CML ABL = Loss of N terminal Cap region of ABL, normally inhibits kinase activity BCR = Gain coil coil of BCR allows dimerization of BCR ABL Results in constitutive activation of the ABL tyrosine kinase. Effects on cellular proliferation, survival and motility Dan Link Heisterkamp, Oncogene, 2002 ;21(56):
17 What cell is transformed in CML? Stem cell Bone marrow Progenitors Blood Terminally differentiated Link NEJM (2006) 354;19, p.2034
18 Colony forming Cell Assay (progenitors) Bone Marrow Cells Culture with specific growth factors for 7-14 days Semi-solid media (methylcellulose) CFU-GM (GM-CSF) BFU-E (Epo)
19 Methylcellulose cultures
20 Hematopoietic Stem Cell Assays HSC Definition: capable of long term (6 months) repopulation of ALL hematopoietic lineages Bone marrow transplantation (gold standard) Xenotransplantation models to assay human HSC Long term culture initiating cell (LTC IC) assay
21 Murine or Xenotransplantation radiation Human hematopoietic cells NOD/SCID mice NOD/SCID gamma (NSG) (immunodeficient) Analyze after 3-6 months for blood cells Mouse hematopoietic donor cells (CD45.2) congenic recipient mice (CD45.1) Analyze after 3-6 months for blood cells
22 Better assays needed to study hematopoiesis Methylcellulose and transplant assays are still the gold standard, but is there a faster, cheaper way to study these cells? How can you prospectively identify the cells and isolate them to study?
23 Flow cytometry
24 Murine or Xenotransplantation Human hematopoietic cells Mouse hematopoietic cells radiation NOD/SCID mice (immunodeficient) CD34+ xenotransplant assays = 1:5000 HSCs CD34+/CD38- = 1:617 HSCs congenic mice (CD45.1/CD45.2) Kit+/Lineage-/Sca+ (KLS) cells = 1:10 HSCs CD150+/CD48- (SLAM) cells = 1:2 HSCs Analyze after 3-6 months for blood cells
25 GOALS: 1) prospectively identify cells using flow cytometry (Weissman group = 1 st mouse, 2 nd human hematopoiesis). 2) Define what cell is transformed in CML (chronic phase and blast crisis). Stem cell Bone marrow Progenitors Blood Terminally differentiated
26 929 citations
27 CMP MEP GMP 288 single cells of each type CMP GMP No Epo+Tpo MEP
28 200 cells each CMP Cytospin of 5 pooled colonies MEP GMP
29 1000 cells on stroma Lineage commitment at CMP single cell level: GMP CMP MEP Single cell sorted
30 Regulation of Hematopoiesis Transcription factors Regulate RNA expression of target genes Critical determinants of lineage commitment and terminal differentiation Frequent targets for mutation in leukemia
31
32
33 HUMAN PROGENITOR ASSAY PNAS (2002)99;18, p.11872
34 What cell is transformed in CML? Stem cell Bone marrow Progenitors Blood Terminally differentiated Link NEJM (2006) 354;19, p.2034
35 Oh Uy Romee Radich CML therapy Lancet (2007)370, p.342
36 Westervelt Oh Uy Radich Targeted therapy (chronic phase) Imatinib = discovered in high throughput screen of kinase inhibitors. NEJM Oct 9;349(15):
37 Issues Cure vs. control of chronic phase CML Resistance in chronic phase CML Treatment of blastic phase CML
Leukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationHematologic Malignancies
Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan
More informationAcute leukemias and myeloproliferative neoplasms
Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is
More informationCytogenetics for the Rest of Us: A Primer
Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen
More informationResponse Definition, Evaluation and Monitoring. Michele Baccarani
Response Definition, Evaluation and Monitoring Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Response definition, evaluation
More informationProject Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D
Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationA disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationTreatment Recommendations for People Living with CML
Treatment Recommendations for People Living with CML Foreword by CML Workgroup Chronic myeloid leukaemia (CML) is a disease of the blood and bone marrow that results when there is a cancerous transformation
More informationA Time Line Of Chronic Myeloid Leukemia
Chronic Myeloid Leukemia in 2011 An Update on Treatment and Monitoring Michael Deininger MD PhD Chief, Division of Hematology and Hematologic Malignancies M. M. Wintrobe Professor of Medicine A Time Line
More informationI was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several
Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationNGS e malattie mieloproliferative
NGS e malattie mieloproliferative Matteo G Della Porta Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia Medical School, Pavia, Italy matteo@haematologica.org
More informationRelative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani
Relative Risk (Sokal & Hasford): Relationship with Treatment Results Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Disease risk
More informationEDUCATIONAL COMMENTARY - GRANULOCYTE FORMATION AND CHRONIC MYELOCYTIC LEUKEMIA
LEUKEMIA Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits under Continuing Education
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationCML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationSynopsis of Causation. Chronic Myeloid Leukaemia
Ministry of Defence Synopsis of Causation Chronic Myeloid Leukaemia Author: Dr M A Vickers, University of Aberdeen, Aberdeen Validator: Professor John Goldman, Hammersmith Hospital, London September 2008
More informationin silico hematology
in silico hematology Application of mathematical modeling to predict the outcome of leukemia treatment by Ingmar Glauche and Ingo Röder Chronic Myeloid Leukemia (CML) accounts for about 20 % of all leukemias
More informationAdult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
More informationWhat is chronic myeloid leukaemia?
Chronic Myeloid Leukaemia What is chronic myeloid leukaemia? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines CHRONIC
More informationDisclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes
Disclosure Equity interest in Genetix Pharm. Inc. Exclusive license of retroviral cell lines from Columbia No direct participation in MDR clinical trials Columbia U. annual reporting FDA Gene Therapy Transfer
More informationThe CML Guide Information for Patients and Caregivers
The CML Guide Information for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC MYELOGENOUS LEUKEMIA MYELOMA Printing of this publication made possible by a grant from A Message from John Walter President
More informationDrug Development Services
Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through
More informationHaematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation
Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Dr Ros Ganderton, Ms Kate Parratt, Dr Debbie Richardson, Dr Kim Orchard and Dr Liz Hodges Departments of Molecular Pathology
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
More informationLa Targeted Therapy e l appropriatezza terapeutica
TRAINING REGIONALE PER FARMACISTI OSPEDALIERI SU LEUCEMIA MIELOIDE CRONICA (LMC), NUOVE TECNOLOGIE ED APPROCCI Roma, 16 Novembre 2015 La Targeted Therapy e l appropriatezza terapeutica Cinzia Dello Russo
More informationBone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate
Original Article Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate Joshi S, Sunita P, Deshmukh C, Gujral S, Amre P, Nair CN Department of Pathology,
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationThe CML Guide. Information for Patients and Caregivers. Chronic Myeloid Leukemia. Matthew, CML survivor. This publication was supported by
The CML Guide Information for Patients and Caregivers Chronic Myeloid Leukemia Matthew, CML survivor This publication was supported by Revised 2014 A Message from Louis J. DeGennaro, PhD President and
More informationCollect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.
Complete Blood Count CPT Code: CBC with Differential: 85025 CBC without Differential: 85027 Order Code: CBC with Differential: C915 Includes: White blood cell, Red blood cell, Hematocrit, Hemoglobin, MCV,
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationAnswering your questions on Chronic Myeloid Leukaemia (CML)
Answering your questions on Chronic Myeloid Leukaemia (CML) Your guide to understanding CML and Glivec (imatinib) treatment The information in this booklet is designed to help you understand chronic myeloid
More informationInteresting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
More informationSubtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.
1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow
More informationRecommendations for the Management of BCR-ABL-positive Chronic Myeloid Leukaemia. British Committee for Standards in Haematology.
Recommendations for the Management of BCR-ABL-positive Chronic Myeloid Leukaemia British Committee for Standards in Haematology. Author; Professor John Goldman Department of Haematology Imperial College
More informationAcute Myelogenous Leukemia Pre-HSCT Data
Instructions for Acute Myelogenous Leukemia Pre-HSCT Data (Form 2010) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the AML Pre-HSCT Data Form. E-mail
More informationStem Cells: The Real Culprits in Cancer?
June 26, 2006 Stem Cells: The Real Culprits in Cancer? A dark side of stem cells--their potential to turn malignant--is at the root of a handful of cancers and may be the cause of many more. Eliminating
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationB Cell Generation, Activation & Differentiation. B cell maturation
B Cell Generation, Activation & Differentiation Naïve B cells- have not encountered Ag. Have IgM and IgD on cell surface : have same binding VDJ regions but different constant region leaves bone marrow
More informationThe Treatment of Leukemia
The Treatment of Leukemia Guest Expert: Peter, MD Associate Professor of Hematology Director, Yale Cancer Center Leukemia Program www.wnpr.org www.yalecancercenter.org Hi, I am Bruce Barber and welcome
More informationOncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
More informationMolecular Biology: Measuring and Reporting BCR-ABL Transcripts Level. Giuseppe Saglio
Molecular Biology: Measuring and Reporting BCR-ABL Transcripts Level Giuseppe Saglio 1 st Question to be addressed Why is it so important to measure BCR- ABL transcript levels in the follow-up of CML patients
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationPeripheral Blood Stem Cell (PBSC) Collections: Why, What, When. Objectives. Sources of Stem Cells
Peripheral Blood Stem Cell (PBSC) Collections: Why, What, When Objectives Why do need stem cell transplants What type of cells are we using for stem cell transplants When and how we collect peripheral
More informationAcute myeloid leukemia (AML)
Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult
More informationMy Sister s s Keeper. Science Background Talk
My Sister s s Keeper Science Background Talk Outline Acute promyelocytic leukemia (APL) APL Treatment Savior Siblings In vitro fertilization (IVF) Pre-implantation Genetic Diagnosis (PGD) Risks of donating
More informationCauses of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands
Causes of Anemia in Patients with Heart Failure Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands Background Anemia is common in patients with CHF Prevalence 15 55%
More informationMyeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies
Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies Robert J. Arceci, M.D., Ph.D. King Fahd Professor of Pediatric Oncology Professor of Pediatrics, Oncology and
More informationChronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
More informationAcute myeloid leukaemia (AML) in children
1 61.02 Acute myeloid leukaemia (AML) in children AML can affect children of any age, and girls and boys are equally affected. Leukaemia Acute myeloid leukaemia (AML) FAB classification of AML Causes of
More informationSpecial report. Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006
Special report Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006 Gene And Protein The gene that causes the mutation is CCND1 and the protein NP_444284 The mutation deals with the cell
More informationUnderstanding Leukemia
Understanding Leukemia Ray, CML survivor Revised 2012 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is the world s largest
More informationWhat Does My Bone Marrow Do?
What Does My Bone Marrow Do? the myelodysplastic syndromes foundation, inc. Illustrations by Kirk Moldoff Published by The Myelodysplastic Syndromes Foundation, Inc. First Edition, 2009. 2012. Table of
More informationAbout B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification
More informationDEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationEmerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
More informationCASE 2. Seven week old female infant presents with hepatosplenomegaly l and WBC 31.0k/mm 3, Hgb 9.2 g/dl, Plt 110k/mm 3 with 60% blasts
CASE 2 Seven week old female infant presents with hepatosplenomegaly l and WBC 31.0k/mm 3, Hgb 9.2 g/dl, Plt 110k/mm 3 with 60% blasts A bone marrow biopsy and aspirate were performed (photos provided).
More informationGenomic Analysis of Mature B-cell Malignancies
Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationEvaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia
Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación
More informationLeukemia-Chronic Myeloid (Myelogenous) Overview
Leukemia-Chronic Myeloid (Myelogenous) Overview This overview is based on the more detailed information in our document, Leukemia- Chronic Myeloid. You can get this document and other information by calling
More informationTutor Prof. Monica Bocchia Dissertation of Dr. Marzia Defina
Doctorate in Genetics, Oncology and Clinical Medicine (GenOMeC) Allergology and clinical and experimental Immunology section XXV cicle Director: Prof. Alessandra Renieri Evaluation of residual CD34+Ph+
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationPathology No: SHS-CASE No. Date of Procedure: Client Name Address
TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,
More informationExercise 9: Blood. Readings: Silverthorn 5 th ed, 547 558, 804 805; 6 th ed, 545 557, 825 826.
Exercise 9: Blood Readings: Silverthorn 5 th ed, 547 558, 804 805; 6 th ed, 545 557, 825 826. Blood Typing The membranes of human red blood cells (RBCs) contain a variety of cell surface proteins called
More informationCancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
More informationinformation for payers and referrers
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in
More informationBoolean Implications Identify Wilms Tumor 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia
Boolean Implications Identify Wilms Tumor 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia Subarna Sinha PhD Department of Computer Science Principal Investigator: David Dill Daniel
More informationCAS Chemistry Research Report Delivering the latest trends in global chemistry research
Delivering the latest trends in global chemistry research Human Genome Discoveries Spur Growth of Cancer Treatments www.cas.org Strength of the Human Genome Project and Targeted Drugs In, President Clinton
More informationImatinib Mesylate in Chronic Myeloid Leukemia: A Prospective, Single Arm, Non-randomized Study
Original Article Imatinib Mesylate in Chronic Myeloid Leukemia: A Prospective, Single Arm, Non-randomized Study C Deshmukh*, T Saikia**, A Bakshi*, P Amare - Kadam***, C Baisane+, P Parikh++ Abstract Chronic
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationProstaglandin E2 Enhances Human Cord Blood Stem. Cell Xenotransplants and Shows Long-Term Safety. in Preclinical Nonhuman Primate Transplant Models
Cell Stem Cell, Volume 8 Supplemental Information Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models Wolfram
More informationSignaling monitoring and flow cytometry
Signaling monitoring and flow cytometry Coultry Club, FIAP Paris April 8, 2014 Dr Jacques Nunès Lymphocyte Activation Group 1 PLAN I Signalisation intracellulaire & «signal monitoring» II Méthodologie
More informationLeukemia Research Foundation 2004-2005 Scientific Research Grant Recipients
Page 1 of 5 NEW INVESTIGATOR AWARDS Ioannis Aifantis, Ph.D. The University of Chicago, Chicago, IL $75,000.00 Cooperation of Notch and pre-tcr Signaling in the Induction of T Cell Leukemia The pre-t Cell
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not
More informationChronic Myeloid Leukaemia: Molecular Abnormalities and Treatment Options
Chronic Myeloid Leukaemia: Molecular Abnormalities and Treatment Options Niamh Appleby, Eimear Burke, Terry-Ann Curran and Elaine Neary, 4 th Year Medicine ABSTRACT Chronic myeloid leukaemia (CML) is a
More informationCHRONIC MYELOGENOUS LEUKEMIA
CHRONIC MYELOGENOUS LEUKEMIA Executive Summary We propose the inclusion of treatment options for chronic myelogenous leukemia (CML), in the category of anti-neoplastic agents, including imatinib, nilotinib,
More informationA practical guide to understanding cancer. Understanding. chronic. myeloid. leukaemia
A practical guide to understanding cancer Understanding chronic myeloid leukaemia Contents 1 Contents About this booklet 3 1 The blood and chronic myeloid leukaemia 5 2 Diagnosing chronic myeloid leukaemia
More informationChildhood Leukemia Overview
Childhood Leukemia Overview What is childhood leukemia? Leukemia is a type of cancer that starts in early forms of blood cells. Cancer starts when cells grow out of control. Cells in nearly any part of
More informationCreation of a Chronic Myeloid Leukemia Retrospective Outcomes Research Registry
Creation of a Chronic Myeloid Leukemia Retrospective Outcomes Research Registry David Stenehjem, Pharm.D. Research Assistant Professor Department of Pharmacotherapy Clinical Hematology/Oncology Pharmacist
More informationFulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
More informationBRIEFING BOOK ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING NDA 22-374. (omacetaxine mepesuccinate)
BRIEFING BOOK ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING NDA 22-374 OMAPRO (omacetaxine mepesuccinate) ChemGenex Pharmaceuticals, Inc. 3715 Haven Avenue, Suite 100 Menlo Park, CA 94025 AVAILABLE FOR PUBLIC
More informationLeukemia and Exposure to Ionizing Radiation
Leukemia and Exposure to Ionizing Radiation Summary: Strong evidence has been recorded of a possible connection between forms of leukemia and exposure to ionizing radiation. This evidence is based upon
More informationProtocol. Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia
Hematopoietic Stem Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 04/01/13 Next Review Date: 03/16 Preauthorization Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12,
More informationTreating Minimal Residual Disease in Acute Leukemias: How low should you go?
Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationCML Drugs and their Availability in the UK. Jane Apperley
CML Drugs and their Availability in the UK Jane Apperley Drugs used in the treatment of CML Traditional chemotherapy Busulphan Hydoxycarbamide Interferon-alpha Omacetaxine Tyrosine kinase inhibitors Imatinib
More informationNCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia
S-1 NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia Susan O Brien, MD; Ellin Berman, MD; Joseph O. Moore, MD; Javier
More informationHow To Expand Hematopoietic Stem Cells
Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population Our bodies are constantly killing old, nonfunctional, and unneeded cells and making
More informationChapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified)
Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified) Assisted Reproductive Technologies (ART) Artificial insemination (AI) In vitro fertilization (IVF) Gamete intrafallopian transfer
More informationProliferation/Potency Assays: Is there more to CD34 and CFU?
Proliferation/Potency Assays: Is there more to CD34 and CFU? CBMTG 2012 Laboratory Committee Meeting April 11, 2012 Toronto, ON, Canada Leah Marquez-Curtis CBS-Edmonton OUTLINE I. Rationale and Definitions
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationCurrent Issues in Stem Cell Technologies. Lance D. Trainor, MD OneBlood, Inc.
Current Issues in Stem Cell Technologies Lance D. Trainor, MD OneBlood, Inc. Objective: The big picture of stem cell therapy Outline: Relevant definitions History of Stem Cell Therapy Hematopoietic Stem
More information